Abstract 151P
Background
Depth of response (DpR) and early tumor shrinkage (ETS) are established predictors of overall survival (OS) in colorectal and gastric cancer; however, data for pancreatic cancer (PC) are limited.
Methods
This study was conducted as part of two multicenter retrospective studies (NAPOLEON and NAPOLEON-2) of patients (pts) with measurable advanced PC tumors. Cohort 1 included 292 pts treated with gemcitabine/nab-PTX (GnP, 184 pts) and FOLFIRINOX (FFX, 108 pts) as first-line chemotherapy, and Cohort 2 included 88 pts treated with nanoliposomal irinotecan, fluorouracil and folinic acid as second-line chemotherapy. DpR was defined as the maximum tumor shrinkage percentage on imaging compared with the pre-treatment level. Pts were divided by DpR into three groups: control (Group A), responder (Group B), and deep responder (Group C). ETS was defined as ≥20% reduction from the start of treatment to the second evaluation.
Results
In Cohort 1, DpR was −2.3 to +1550% in Group A, −28.6 to −2.5% in Group B, and −100.0 to −28.6% in Group C. The baseline C-reactive protein/albumin ratio differed significantly by group (p=0.04). The median OS (mOS) was significantly longer in Group C (17.2 months) and Group B (11.5 months) than in Group A (8.4 months), (hazard ratio [HR], 95% confidence interval [CI]: 0.30, 0.22–0.42, p<0.01; and 0.58, 0.43–0.79, p<0.01, respectively). The mOS was also significantly longer in the ETS group overall (HR 0.46, 95% CI 0.35–0.61, p<0.01) and in both the GnP and FFX subgroups. In Cohort 2, DpR was +18.4 to +128.6% in Group A, −2.9 to +17.9% in Group B, and −80.0 to −3.2% in Group C. The baseline prevalence of ascites differed significantly by group (p=0.04). The mOS was significantly longer in Group C (10.9 months) than in Group A (4.6 months; HR 0.33, 95% CI 0.17–0.65, p<0.01), but mOS in Group B (6.8 months) did not differ significantly from Group A (p=0.10).
Conclusions
This is the first report that DpR and ETS might be predictors of OS in pts with PC on standard chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract